ClinicalTrials.gg
Not yet recruitingNCT07663695Updated Jun 23, 2026

Propofol vs. Ciprofol for Anesthesia Induction in Frail Elderly Patients

An interventional study of Ciprofol and Propofol in Hypotension, sponsored by General Hospital of Ningxia Medical University. Not yet recruiting at 1 site in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by General Hospital of Ningxia Medical University · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Hypotension with a site in China — 26 open to participants now, 29 under way, none of them phase 3. Hypotension · China.

Planned enrollment
27th of 40
96 · median 129
Started
2026
with 10 others
No phase
26 of 59
12 open now
Primary completion
2026-12
later than 15 of 28 live
Registered
54th of 59
by date
Lead sponsor
5 of 59
General Hospital of Ningxia Medical University

Among the 59 studies in Hypotension with a site in China, this one is the 27th largest by planned enrollment of the 40 interventional ones that give a count, is one of 11 that started in 2026, is one of 26 with no phase, reaches primary completion later than 15 of the 28 other live ones, and was the 54th registered.

Hypotension

892 studies on the registry are indexed under Hypotension; 199 are open to participants now.

Browse Hypotension studies →

Open to participants now

26 of the 59 studies in Hypotension with a site in China are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 114 Hypotension studies recruiting now, 53 (46%) set no upper age limit and 36 (32%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Hypotension with a site in China, or all of them as a file.
02

Study summary

Post-induction hypotension (PIH) is a common and critical complication during general anesthesia, particularly in frail elderly patients whose physiological reserves are significantly diminished. PIH is strongly associated with adverse postoperative outcomes, including acute kidney injury (AKI) and myocardial injury. Propofol is the most widely used induction agent but frequently induces circulatory depression. Ciprofol, a novel anesthetic agent developed by optimizing the molecular structure of propofol, has demonstrated improved hemodynamic stability and fewer adverse effects in general populations. However, its specific impact on frail elderly patients remains unestablished.

The primary purpose of this single-center, randomized, double-blind, controlled trial is to compare the effects of propofol and ciprofol during anesthesia induction on the incidence of PIH in frail elderly patients undergoing major abdominal surgery. The investigator's hypothesis is that ciprofol will significantly lower the incidence of PIH compared to propofol. Additionally, the study will evaluate secondary clinical outcomes, such as postoperative AKI, postoperative cardiac complications, and the overall quality of recovery, to provide an evidence-based clinical guide for selecting optimal induction agents for this vulnerable patient population.

Read the detailed description

Background and Rationale:

Frail elderly patients exhibit an accumulation of multi-system physiological decline, making them highly vulnerable to surgical and anesthetic stressors. During the induction of general anesthesia, these patients are at an exceptionally high risk for severe and prolonged hypotension due to reduced cardiac stroke volume, impaired autonomic nervous system regulation, and altered pharmacokinetics. Post-induction hypotension (PIH)-occurring from the initiation of anesthesia to 10 minutes post-intubation-is directly influenced by the choice of induction agent and the patient's baseline condition, with fewer confounding factors than intraoperative hypotension.

While propofol is highly efficient, its prominent side effect is cardiovascular depression. Ciprofol is an innovative 2,6-disubstituted phenol derivative that maintains the rapid onset and recovery advantages of propofol while offering enhanced hemodynamic stability. To date, clinical evidence comparing these two agents specifically in the frail elderly population is lacking. This study seeks to evaluate whether ciprofol can mitigate the risk of PIH in frail elderly patients undergoing major abdominal surgery and to observe its downstream impacts on major organ protection and postoperative recovery quality.

Study Workflow and Anesthesia Management:

  1. Patient Screening: Patients aged 60 or older with a frailty score >= 3 undergoing major abdominal surgery under general anesthesia with planned invasive blood pressure monitoring will be screened on the day before surgery.
  2. Randomization and Blinding: Eligible participants will be randomized in a 1:1 ratio to either the Propofol Group or the Ciprofol Group. Both patients and outcome assessors will be blinded to the group allocation.
  3. Intervention:

    • Propofol Group: Anesthesia induction will be performed using midazolam, sufentanil, propofol, and rocuronium.
    • Ciprofol Group: Anesthesia induction will be performed using midazolam, sufentanil, ciprofol, and rocuronium.
  4. Monitoring and Follow-up: Standardized intraoperative and perioperative management will be applied uniformly across both groups. Hemodynamic parameters will be monitored continuously. Postoperatively, patients will be followed up to evaluate acute kidney injury (AKI) within 48 hours, cardiac complications (including MINS, congestive heart failure, and acute myocardial infarction) within 7 days or during hospitalization, and overall recovery quality metrics (including mechanical ventilation time, PACU and ICU stay duration, and total postoperative hospital stay).
03

Conditions studied

  • Hypotension

Browse trials for

Keywords

  • Propofol
  • Ciprofol
  • Anesthesia Induction
  • Frail Elderly
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled to undergo major abdominal surgery under general anesthesia.
  • Frailty score >= 3[cite: 2].
  • Age >= 60 years[cite: 2].
  • (ASA) physical status class >= II[cite: 2].
  • Planned invasive blood pressure monitoring[cite: 2].

Exclusion criteria

Exclusion Criteria:

  • Severe cardiac arrhythmia[cite: 2].
  • Severe valvular heart disease[cite: 2].
  • Poorly controlled hypertension with medication (systolic blood pressure >= 180 mmHg and/or diastolic blood pressure >= 110 mmHg)[cite: 2].
  • Pre-existing preoperative hypotension (mean arterial pressure \< 65 mmHg)[cite: 2].
  • Preoperative renal dysfunction (serum creatinine greater than the )[cite: 2].
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Ciprofol

    Frail elderly patients undergoing major abdominal surgery who receive ciprofol for general anesthesia induction, combined with midazolam, sufentanil, and rocuronium.

    Drug: Ciprofol

  • Active comparator
    Propofol Group

    Frail elderly patients undergoing major abdominal surgery who receive propofol for general anesthesia induction, combined with midazolam, sufentanil, and rocuronium.

    Drug: Propofol

Interventions

  • An innovative 2,6-disubstituted phenol derivative used for general anesthesia induction.

  • An alkylphenol derivative and standard intravenous anesthetic agent used for general anesthesia induction.

06

What researchers measure

Primary outcomes

  1. Incidence of post-induction hypotension (PIH)

    Post-induction hypotension (PIH) is defined as a mean arterial pressure (MAP) \< 65 mmHg lasting for more than 1 minute.

    Time frame: From the initiation of general anesthesia drug administration until 10 minutes after endotracheal intubation.

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Dec 2026, 6 months later.

Of 213 non-industry interventional studies with no phase under Hypotension, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 6 months is below that.

Counting every sponsor, half of 220 studies reached it within 12 months; a quarter within 6 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2026
First posted
Jun 23, 2026
StartEst.
Jun 25, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jan 31, 2027
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07663695
Responsible party
Sponsor
First posted
Jun 23, 2026
Start date
Jun 25, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Jun 23, 2026

Study contacts

Hongmei Ma
Contact
13909713260@138.com
+86 13909713260

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ciprofol

Start the discussion